Translating Dermatology to the Gut: Adial's High-Stakes Bet on AhR Agonists

GLEN ALLEN, Va. – October 16, 2026 – The biological mechanisms that govern human inflammation are notoriously complex, often requiring developers to thread a microscopic needle between therapeutic efficacy and systemic toxicity. For Adial Pharmaceuticals, threading that needle in the gastrointestinal tract has become the core focus of a sweeping corporate transformation.

The clinical-stage biopharmaceutical company announced today the appointment of David Rubenstein, M.D., Ph.D., as its new Chief Scientist. Dr. Rubenstein is tasked with steering the company's lead candidate, AT177—a proprietary, oral, colon-targeted aryl hydrocarbon receptor (AhR) agonist—through IND-enabling studies toward first-in-human trials slated for 2027.

The appointment is far more than a routine executive shuffle. It represents a highly calculated move to capture a proven scientific architect. During his tenure as Chief Scientific Officer at Dermavant Sciences, Dr. Rubenstein successfully navigated tapinarof (VTAMA cream 1%) through the perilous drug development pipeline. Tapinarof ultimately became the first and only AhR agonist approved by the U.S. Food and Drug Administration, establishing AhR agonism as a clinically validated mechanism for immune-mediated inflammatory diseases like plaque psoriasis and atopic dermatitis. Now, Adial is betting that Dr. Rubenstein can replicate that dermatology triumph in the gut.

From Botanical Roots to Precision Synthetic Medicine

To understand the promise of AT177, one must look at its origins in traditional medicine. The drug's active ingredient is a synthetic prodrug of indirubin. Indirubin itself is widely recognized as one of the most potent AhR agonists found in indigo naturalis, a botanical extract that has been used for centuries and has recently exhibited remarkably strong clinical activity and remission rates in modern ulcerative colitis (UC) trials.

However, the transition from folk remedy to modern pharmaceutical is rarely seamless. While indigo naturalis has shown high efficacy in inducing clinical response in patients with moderate-to-severe and treatment-refractory UC, long-term use has been plagued by severe safety concerns. Most notably, unrefined botanical extracts have been linked to instances of pulmonary arterial hypertension (PAH) and mild liver dysfunction. These systemic risks previously led to the termination of at least one randomized controlled trial investigating indigo naturalis.

This is the precise pharmacological hurdle AT177 is engineered to clear. By designing a fully synthetic prodrug, developers aim to achieve "gut-restricted delivery." The goal is to maximize local colonic delivery of indirubin, restoring mucosal immune homeostasis exactly at the site of the disease, while starving the rest of the body of systemic exposure. Preclinical studies have thus far supported this hypothesis, demonstrating colon concentrations of indirubin that are over 100-fold greater than plasma concentrations.

Translating a Dermatology Triumph to the Gut

The aryl hydrocarbon receptor is a ligand-activated transcription factor expressed in various tissues, including the intestinal lining. In patients with inflammatory bowel disease (IBD), AhR activity is often markedly decreased. Activating this receptor is crucial because it triggers the production of interleukin-22 (IL-22), which enhances epithelial barrier function, alters gut microbiota, and aggressively downregulates pro-inflammatory mediators to promote mucosal healing.

Dr. Rubenstein's success with VTAMA proved that targeting this specific receptor could effectively quiet inflammatory pathways in the skin. The challenge now lies in oral delivery and localized activation within the harsh environment of the human digestive tract.

"Dave is one of very few drug developers who has taken an AhR agonist all the way from the lab to patients, and that experience maps directly to what we are building with AT177," said Matt Davidson, Ph.D., Chief Development Officer and Director of Adial. "We believe that his understanding of AhR pharmacology, translational science and the regulatory path for a first-in-class mechanism will be invaluable as we complete IND-enabling work and prepare to enter the clinic next year."

For his part, Dr. Rubenstein views the transition from skin to colon as a logical, albeit challenging, scientific progression.

"Tapinarof demonstrated what targeted AhR activation can do for patients with inflammatory disease," Dr. Rubenstein added. "The goal now is to bring that biology to the colon while keeping systemic exposure low, which is exactly how AT177 is being designed. I'm excited to join Matt and the team at this stage and to help advance a new oral approach for people with ulcerative colitis who still lack durable treatment options."

A High-Stakes Corporate Transformation

Behind the molecular biology lies a dramatic corporate pivot. Adial Pharmaceuticals was previously best known for its work in addiction treatment, specifically its AD04 program for alcohol use disorder. The shift toward gastroenterology was catalyzed in June 2026 when Adial acquired Azora Therapeutics in a stock-for-stock transaction, bringing AT177 into its pipeline.

Concurrent with the acquisition, the firm secured an initial upfront financing of approximately $32 million, with the potential for an additional $32 million upon the initiation of Phase 1 clinical trials. This capital injection is designed to fund the combined entity through early clinical development.

However, the post-merger integration has not been without financial friction. In August 2026, the company received a deficiency notice from Nasdaq, indicating that its stockholders' equity had fallen below the $2.5 million minimum requirement for continued listing.

To rectify this and stabilize its market position, the company is executing a complex financial restructuring. Management is seeking stockholder approval to convert over 12,000 shares of newly created Series A non-voting convertible preferred stock—issued during the Azora acquisition—into common stock. Furthermore, in September, the firm amended its warrant agreements to remove penalty provisions and add lock-up terms, a maneuver designed to alter the accounting treatment of milestone warrant rights from liabilities to equity. Successfully navigating these financial and regulatory roadblocks is just as critical to AT177's future as the upcoming IND-enabling studies.

The Competitive Landscape of IBD

If Adial can maintain its financial footing and push AT177 into the clinic by 2027, it will enter a highly lucrative but fiercely competitive market. The global IBD treatment market was valued at approximately $26.55 billion in 2023 and is projected to approach $36 billion by the next decade.

Currently, the market is seeing a massive shift toward oral therapies, driven by patient preference for pills over injectables or infusions. While oral small molecule JAK inhibitors like upadacitinib (Rinvoq) have set a high efficacy bar, they carry severe boxed warnings for cardiovascular events, malignancy, and life-threatening infections. This has created a massive unmet need for oral therapies that can deliver deep, durable remission without acting as broad, systemic immunosuppressants.

Adial is not alone in recognizing the potential of AhR agonism for IBD. Competitors like Equillium, with its preclinical candidate EQ-504, and Aqilion, developing the oral small-molecule AQ312, are also racing to validate this pathway in the gut.

By bringing on the scientist who literally wrote the regulatory playbook for the first approved AhR agonist, Adial is signaling to the market that it intends to lead this specific biological niche. As the company finalizes its preclinical work over the next twelve months, the biopharma industry will be watching closely to see if the success of dermatology's most targeted new mechanism can indeed be swallowed, surviving the journey to heal the colon from within.